We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Microfluidic Motility Device Indicates Likelihood of Breast Tumor Metastasis

By LabMedica International staff writers
Posted on 10 Jun 2019
Print article
Image: Examples of migratory and non-migratory MDA-MB-231 breast cancer cells migrating in the MAqCI (Microfluidic Assay for quantification of Cell Invasion) device (Photo courtesy of Christopher L. Yankaskas, Johns Hopkins University).
Image: Examples of migratory and non-migratory MDA-MB-231 breast cancer cells migrating in the MAqCI (Microfluidic Assay for quantification of Cell Invasion) device (Photo courtesy of Christopher L. Yankaskas, Johns Hopkins University).
A novel microfluidic motility test was shown to accurately predict a breast tumor's likelihood to generate metastases.

The difficulties involved in predicting which patients with breast cancer will develop metastases leads to the overtreatment of patients with benign disease and to the inadequate treatment of aggressive cancers. To meet this predictive challenge, investigators at Johns Hopkins University (Baltimore, MD, USA) development a microfluidic assay that quantified the abundance and proliferative index of migratory cells in breast cancer specimens, for the assessment of their metastatic propensity and for the rapid screening of potential anti-metastatic therapeutics.

The device comprised Y-shaped microchannels with dimensions chosen to mimic aspects of the complexity and variety of the cross-sectional areas of tissue tracks found in or along different locations in the body. This Microfluidic Assay for quantification of Cell Invasion (MAqCI) was designed to evaluate three key features of metastasis: cancer cells’ ability to move, their ability to compress in order to enter narrow channels, and their ability to proliferate.

The MAqCI device, which is now patented in the United States, was used in conjunction with a computerized inverted microscope having phase contrast and fluorescence imaging capabilities. Cell migration was monitored in real time via time-lapse phase contrast microscopy. Results of experiments conducted with the MAqCI device revealed that compared to an unsorted population of cancer cells, highly motile cells isolated by the device exhibited similar tumorigenic potential but markedly increased metastatic propensity in vivo.

RNA sequencing of the highly motile cells revealed an enrichment of motility-related and survival-related genes.

“When a lump is detected in a patient’s body, the doctor can determine if the mass is benign or malignant through a biopsy, but they cannot really say with confidence if a malignant tumor is going to be highly aggressive and metastasize to other locations,” said senior author Dr. Konstantinos Konstantopoulos, professor of biomedical engineering and oncology at Johns Hopkins University. “Although liquid biopsies or circulating tumor DNA measurements can be very good at monitoring a patient’s response to therapy after it is administered, they do not provide a means to help physicians select optimal drugs to prevent spread.”

Use of the MAqCI device was described in the May 6, 2019, online edition of the journal Nature Biomedical Engineering.

Related Links:
Johns Hopkins University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.